VERVE THERAPEUTICS IN

4.4050

20-May-25 10:06:46

15 minutes delayed

Stocks

+0.0350

+0.80%

Today's range

4.3200 - 4.5000

ISIN

N/A

Source

NASDAQ

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2024 16:05:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

28 Jun 2024 07:00:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

31 May 2024 16:01:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Leadership Update

31 May 2024 07:00:00 By Nasdaq GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences

30 May 2024 16:01:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

08 May 2024 07:00:01 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

07 May 2024 07:00:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 16:01:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Updates on its PCSK9 Program

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

28 Mar 2024 16:51:34 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 16:01:00 By Nasdaq GlobeNewswire
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

27 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 Feb 2024 06:30:00 By Nasdaq GlobeNewswire
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 06:30:11 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

01 Dec 2023 16:00:00 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

28 Nov 2023 22:37:08 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

28 Nov 2023 16:01:51 By Nasdaq GlobeNewswire
Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

07 Nov 2023 06:30:00 By Nasdaq GlobeNewswire
Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

31 Oct 2023 06:01:28 By Nasdaq GlobeNewswire
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

23 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.